{"id":46874,"date":"2025-02-12T14:15:03","date_gmt":"2025-02-12T13:15:03","guid":{"rendered":"https:\/\/www.maiwald.eu\/presseberichte\/royalty-pharma-announces-250m-rd-funding-collaboration-with-biogen\/"},"modified":"2025-02-13T14:17:08","modified_gmt":"2025-02-13T13:17:08","slug":"royalty-pharma-announces-250m-rd-funding-collaboration-with-biogen","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/cn\/presseberichte\/royalty-pharma-announces-250m-rd-funding-collaboration-with-biogen\/","title":{"rendered":"Royalty Pharma Announces $250M R&amp;D Funding Collaboration with Biogen"},"content":{"rendered":"\n<p><strong>New York, NY, February 12, 2025<\/strong> \u2013 Royalty Pharma (Nasdaq: RPRX) has entered into an agreement with Biogen to provide up to $250 million in research and development (R&amp;D) funding for litifilimab, a first-in-class investigational biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).<\/p>\n\n\n\n<p>&#8220;Litifilimab has the potential to significantly improve treatment outcomes for lupus patients,&#8221; said Pablo Legorreta, CEO of Royalty Pharma. &#8220;We are excited to support its Phase 3 development through this funding collaboration.&#8221;<\/p>\n\n\n\n<p>Under the agreement, Royalty Pharma will fund Biogen over six quarters in exchange for regulatory milestones and mid-single digit royalties on worldwide sales. Litifilimab has demonstrated proof of concept with a well-tolerated safety profile, and results from Phase 3 trials are expected between 2026 and 2027.<\/p>\n\n\n\n<p>Maiwald acted as legal advisors to Royalty Pharma.<\/p>\n\n\n\n<p><strong>About Royalty Pharma<\/strong><br>Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties, partnering across the industry to fund innovation. Its portfolio includes royalties on more than 35 commercial products, such as Trikafta, Evrysdi, and Imbruvica.<\/p>\n\n\n\n<p>This text is a summary of an article published by Royalty Pharma. The full text of the article is available <a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-announces-rd-funding-collaboration-with-biogen\/\" data-type=\"link\" data-id=\"https:\/\/www.juve-patent.com\/cases\/epo-swerves-the-matter-of-granting-genetic-scissor-patents-crispr-cas\/\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-46874","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/46874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/46874\/revisions"}],"predecessor-version":[{"id":46879,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/46874\/revisions\/46879"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=46874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}